These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14962253)

  • 21. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
    Grdisa M
    Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
    Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
    Chakrabarti S; MacDonald D; Hale G; Holder K; Turner V; Czarnecka H; Thompson J; Fegan C; Waldmann H; Milligan DW
    Br J Haematol; 2003 Apr; 121(1):109-18. PubMed ID: 12670340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.
    Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D
    Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
    Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
    Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
    Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
    Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
    Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
    Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity.
    Condiotti R; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.
    Montillo M; Tedeschi A; Rossi V; Cairoli R; Pungolino E; Intropido L; Cafro AM; D'Avanzo G; Farioli R; Brando B; Scarpati B; Veronese S; Morra E
    Leukemia; 2004 Jan; 18(1):57-62. PubMed ID: 14586480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
    Thachil J; Salim R
    Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
    [No Abstract]   [Full Text] [Related]  

  • 35. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia.
    Doney KC; Chauncey T; Appelbaum FR;
    Bone Marrow Transplant; 2002 May; 29(10):817-23. PubMed ID: 12058231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
    Cortelezzi A; Viganò M; Zilioli VR; Fantini NN; Pasquini MC; Deliliers GL; Colombo M; Lampertico P
    J Clin Virol; 2006 Apr; 35(4):467-9. PubMed ID: 16316778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
    Chalandon Y; Roosnek E; Mermillod B; Waelchli L; Helg C; Chapuis B
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):102-10. PubMed ID: 16399574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
    Ritgen M; Böttcher S; Stilgenbauer S; Bunjes D; Schubert J; Cohen S; Humpe A; Hallek M; Kneba M; Schmitz N; Döhner H; Dreger P;
    Leukemia; 2008 Jul; 22(7):1377-86. PubMed ID: 18418404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.